Research programme: antibody drug conjugates - ADC Therapeutics

Drug Profile

Research programme: antibody drug conjugates - ADC Therapeutics

Alternative Names: ADCT 501; ADCT 502; ADCT 601

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator ADC Therapeutics; Cancer Research Technology
  • Class Immunoconjugates
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bladder cancer; Breast cancer; Gastric cancer; Lung cancer; Multiple myeloma; Oesophageal cancer

Most Recent Events

  • 05 Jan 2017 Preclinical trials in Bladder cancer in United Kingdom (Parenteral)
  • 05 Jan 2017 Preclinical trials in Breast cancer in United Kingdom (Parenteral)
  • 05 Jan 2017 Preclinical trials in Lung cancer in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top